- Home
- CBIO vs NPCE Comparison
CBIO vs NPCE Comparison
Compare CBIO & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- NPCE
- Stock Information
- Founded
- CBIO 2003
- NPCE 1997
- Country
- CBIO United States
- NPCE United States
- Employees
- CBIO N/A
- NPCE N/A
- Industry
- CBIO
- NPCE Medical Specialities
- Sector
- CBIO
- NPCE Health Care
- Exchange
- CBIO Nasdaq
- NPCE Nasdaq
- Market Cap
- CBIO 308.0M
- NPCE 292.9M
- IPO Year
- CBIO N/A
- NPCE 2021
- Fundamental
- Price
- CBIO $14.29
- NPCE $9.15
- Analyst Decision
- CBIO Strong Buy
- NPCE Strong Buy
- Analyst Count
- CBIO 5
- NPCE 6
- Target Price
- CBIO $25.60
- NPCE $16.67
- AVG Volume (30 Days)
- CBIO 98.3K
- NPCE 205.3K
- Earning Date
- CBIO 07-31-2025
- NPCE 08-12-2025
- Dividend Yield
- CBIO N/A
- NPCE N/A
- EPS Growth
- CBIO N/A
- NPCE N/A
- EPS
- CBIO N/A
- NPCE N/A
- Revenue
- CBIO N/A
- NPCE $88,570,000.00
- Revenue This Year
- CBIO N/A
- NPCE $22.13
- Revenue Next Year
- CBIO N/A
- NPCE $6.07
- P/E Ratio
- CBIO N/A
- NPCE N/A
- Revenue Growth
- CBIO N/A
- NPCE 23.32
- 52 Week Low
- CBIO $10.83
- NPCE $5.45
- 52 Week High
- CBIO $21.40
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- CBIO 52.92
- NPCE 51.74
- Support Level
- CBIO $13.50
- NPCE $8.61
- Resistance Level
- CBIO $16.00
- NPCE $8.99
- Average True Range (ATR)
- CBIO 0.79
- NPCE 0.53
- MACD
- CBIO 0.16
- NPCE 0.11
- Stochastic Oscillator
- CBIO 39.68
- NPCE 75.00
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.